Assessment of North America’s Antibiotics Market 2019-2027: Impact of COVID-19 on the $18+ Billion-Projected Industry – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “North America Antibiotics Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country” report has been added to ResearchAndMarkets.com’s offering.

The North American antibiotics market is expected to reach US$ 18,004.25 million by 2027 from US$ 13,527.79 million in 2019. The market is estimated to grow with a CAGR of 3.9% from 2020 to 2027.

The antibiotics market is growing primarily due to prevalence of infectious diseases and increasing development of generic drugs in the North America region. Restraining factors, such as tedious and expensive process of antibiotic development is likely to slow down the growth of the market in the coming years. Additionally, growing investments to combat antimicrobial resistance and incorporation of novel computing technologies for antibiotics discovery are likely to increase the growth of the Antibiotics market in the forecast period.

The prevalence of infectious disease, especially caused by bacteria is increasing day by day. According to a study published by the American Society for Microbiology (ASM) in 2019, Carbapenem-resistant bacterial infections risk factor leads to ~49,000 hospitalization cases in the US each year. Moreover, according to CDC, in 2018, there were around 49,157 pneumonia deaths, which accounted for 15:1 per 100,00 people; moreover, in the United States, an estimated 48 million foodborne diarrhea illnesses occur annually, resulting in more than 128,000 hospitalizations and 3,000 deaths.

According to CDC, campylobacter causes an estimated 1.5 million illnesses each year in the United States. Thus, the increasing prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period. (Read more…) The prevalence of antimicrobial resistant bacteria is also increasing in developing and developed countries. Thus, the increasing prevalence of such drug-resistant bacteria compels the manufacturers and R&D faculties to come up with new effective variants of antimicrobials against the new and old bacterial strains, thereby fueling the growth of the antibiotics market.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak. This has eventually shifted their focus from development of new antibiotics to vaccine development for COVID-19. Moreover, diversion of resources from antibiotics development to coronavirus treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, pharmaceutical supplies and procurement are also badly affected by the outbreak of COVID-19 in North America.

In 2019, the cephalosporin segment accounted for the largest share of the market; it is further expected to continue its dominance during the forecast period. This class of antibiotics is usually safe due to low toxicity to self-cells and remarkable efficiency against susceptible bacteria. On the other hand, fluoroquinolones are expected to register the highest CAGR in the antibiotics market during 2020-2027.

Key Topics Covered

1. Introduction

1.1 Scope of the Study

1.2 Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Antibiotics Market – By Drug Class

1.3.2 North America Antibiotics Market – By Action Mechanism

1.3.3 North America Antibiotics Market – By Country

2. North America Antibiotics Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Antibiotics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Antibiotics Market – North America PEST Analysis

4.3 Expert Opinion

5. North America Antibiotics Market – Key Market Dynamics

5.1 Key Market Drivers

5.1.1 Rising Prevalence of Bacterial Infections

5.1.2 Increasing Development of Generic Drugs

5.2 Key Market Restraints

5.2.1 Tedious and Expensive Process of Antibiotic Development

5.3 Market Opportunities

5.3.1 Growing Investments to Combat Antimicrobial Resistance

5.4 Future Trends

5.4.1 Incorporation of Novel Computing Technologies for Antibiotics Discovery

5.5 Impact analysis

6. Antibiotics Market – North America Analysis

6.1 North America Antibiotics Market Revenue Forecasts and Analysis

7. North America Antibiotics Market Analysis and Forecasts to 2027 – By Drug Class

7.1 Overview

7.2 North America Antibiotics Market, By Drug Class 2019 & 2027 (%)

7.3 Sulfonamides

7.4 Aminoglycosides

7.5 Carbapenem

7.6 Macrolides

7.7 Fluoroquinolones

7.8 Penicillin

7.9 Cephalosporins

7.10 Others

8. North America Antibiotics Market Analysis – By Action Mechanism

8.1 Overview

8.2 North America Antibiotics Market, By Action Mechanism 2019-2027 (%)

8.3 Mycolic Acid Inhibitors

8.4 RNA Synthesis Inhibitors

8.5 DNA Synthesis Inhibitors

8.6 Protein Synthesis Inhibitors

8.7 Cell Wall Synthesis Inhibitors

8.8 Others

9. Antibiotics Market Revenue and Forecasts to 2027 – Geographical Analysis

10. Impact of COVID-19 Pandemic on North America Antibiotics Market

11. Company Profiles

11.1 Pfizer Inc.

11.2 Johnson & Johnson Services, Inc.

11.3 Bristol-Myers Squibb Company

11.4 Eli Lilly and Company

11.5 Abbott

For more information about this report visit https://www.researchandmarkets.com/r/qth07k



Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.